AveXis
British baby’s death not caused by Zolgensma says Novartis
September 19, 2019Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy
Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …
Novartis exec pushed out over Zolgensma data scandal denies wrongdoing
August 21, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma
Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
Novartis exec sold off shares before Zolgensma data scandal was revealed
August 19, 2019Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …
Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal
August 13, 2019Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc
Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …
Senators call on FDA to use “forceful response” against Novartis over faulty data scandal
August 12, 2019Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma
Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …
Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma
August 7, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma
Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy
May 28, 2019Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma
The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …
Novartis CEO makes mark with $8.7bn AveXis acquisition
April 9, 2018Sales and Marketing AveXis, Novartis, biotech, drugs, gene therapy, pharma, pharmaceutical
Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …
Latest content
FibroFind appoints Lee Borthwick as CEO
